In a cohort of de novo PD patients, RBD and RWA were analysed using video-supported polysomnography (vPSG). In 158 participants, the proportion of patients with RBD rose from 25% at baseline to 52% at 6 years. In the subsequent RWA analysis, 31 patients with RBD were included for whom a complete set of 4 vPSG readings (at baseline, 2 years, 4 years, and 6 years) was available. The mean age of this group at baseline was 60 years. Over 6 years, RWA increased from baseline by 0.26 points every 2 years on a logarithmic scale (P<0.001). The rate of RWA rose from 19% at baseline, to 29% at 2 years, 33% at 4 years, and 41% at 6 years (P<0.001). Age was the only independent factor influencing RWA increase (P=0.04). Sex, levodopa equivalent daily dose, Movement Disorder Society-Unified Parkinsonâs Disease Rating Scale (MDS-UPDRS), and benzodiazepine intake did not have any statistical significant influence.
- Muntean M-L, et al. Abstract O4021, EAN 2020.
Posted on
Previous Article
« Long-term safety of ND0612 in idiopathic PD Next Article
White matter matters in Parkinsonâs disease »
« Long-term safety of ND0612 in idiopathic PD Next Article
White matter matters in Parkinsonâs disease »
Table of Contents: EAN 2020
Featured articles
Alzheimer's Disease and Other Dementias
Non-Alzheimerâs disease pathophysiology in the elderly
Novel genetic association with resistance to ERC tau deposition
Diastolic dysfunction novel risk factor for cognitive impairment
Epilepsy
Avoidable epilepsy-related mortality remains high
How genetic testing can contribute to epilepsy management
Cenobamate effective in focal epilepsy
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome
Prevalence of autoantibodies in epilepsy almost 10%
Parkinson's Disease
White matter matters in Parkinsonâs disease
Sleep disorders mark PD progression
Directional DBS superior to omnidirectional DBS
Stroke
Benefits of statins to prevent stroke outweigh risks
Extubation after thrombectomy: the sooner, the better
Thrombus location and length predictors of early neurological deterioration
Endovascular treatment in large vessel occlusion stroke patients treated with OAC
Early edoxaban may be safe after cardioembolic stroke
Headache and Pain
Small fibre pathology as biomarker for fibromyalgia
Migraine as a cyclical functional disorder
Reassuring real-world safety profile of 3 CGRP inhibitors
Long-term cardiovascular safety of erenumab
Real-world data for erenumab in Germany
Eptinezumab in chronic migraine and medication-overuse headache
Fremanezumab tolerability in cardiovascular patients with migraine
Effects of galcanezumab on health-related quality of life
Multiple Sclerosis
Imaging to evaluate remyelination and neuroprotection
Serum NfL predicts long-term clinical outcomes in MS
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
High NEDA rates after 2 years of ocrelizumab
Switching from natalizumab to moderate- versus high-efficacy DMT
Results of compounds in late stages of development
Alemtuzumab efficacy and safety data of over 9 years
Fampridine treatment results in routine clinical practice
Air pollution is a possible risk factor for MS
Neuromyelitis Optica Spectrum Disorder
Genetic association studies in NMOSD needed
Eculizumab in NMOSD: the PREVENT study
Long-term safety of satralizumab consistent with double-blind periods
Neuromuscular Disorders
Biomarkers predicting motor function in SMA
Sustained benefits of avalglucosidase alfa in late-onset Pompe disease
Efficacy and safety of rituximab in refractory MG corroborated
Related Articles
September 9, 2020
Fremanezumab tolerability in cardiovascular patients with migraine
September 10, 2020
Migraine as a cyclical functional disorder
September 9, 2020
Unmet needs and pipeline
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com